Key Summary Points {#FPar1}
==================

**Why carry out this study?**• Gout is a painful, inflammatory condition caused by persistently elevated serum uric acid levels. Oral medications to lower serum uric acid can fail, leaving pegloticase as the only treatment option for uncontrolled disease (frequent gout flares, tophi, and joint disease).• Pegloticase converts uric acid to a form the body can easily excrete. However, some uncontrolled gout patients develop anti-drug antibodies to pegloticase, which causes a loss of efficacy and increases the risk for infusion reactions. Because of this, physicians have begun to use immunomodulatory medicines, such as methotrexate, to prevent this immune response.• This study was done to see if patients treated with both pegloticase and methotrexate had better response rates than with pegloticase alone. Responder was defined as a ≥12 biweekly pegloticase infusion therapy course with a serum uric acid level \< 6 mg/dL just prior to infusion 12.**What was learned from the study?**• The response rate with methotrexate/pegloticase co-therapy was 80%, which was higher than the established 42% with pegloticase alone.• Methotrexate immunomodulation with pegloticase therapy was well tolerated and may allow more patients with uncontrolled gout to benefit from a full treatment course.

Introduction {#Sec1}
============

Gout is an inflammatory disease triggered by elevated serum uric acid levels (sUA). A 2015--2016 national health study found that 9.2 million Americans are affected by gout \[[@CR1]\], up from an estimated 8.3 million in 2007--2008 \[[@CR2]\]. Needle-like monosodium urate crystals form when sUA levels rise above its serum solubility limit (6.8 mg/dl). These crystals then deposit on bones, in joints, and in soft tissues (including organs and cartilage) \[[@CR3]\] and result in chronic inflammation throughout the body. This inflammation persists, even between gout flares when many patients do not exhibit classic gout symptoms (high levels of pain, joint swelling and redness). Joint pain and bone erosion commonly occur in patients with urate deposition, particularly in patients with uncontrolled gout.

Maintaining sUA levels below 6 mg/dl reduces the number of gout flares \[[@CR4]\] and can reduce the size and number of tophi \[[@CR5]\]. As a result, this is the recommendation of both American \[[@CR6]\] and European \[[@CR7]\] guidelines for gout management. Recommended sUA levels are even lower for patients with severe gout \[[@CR6]--[@CR8]\] (\< 5 mg/dl \[[@CR7], [@CR8]\]), characterized by frequent gout flares, subcutaneous (visible) tophi, and chronic gouty arthritis. Unfortunately, some gout patients cannot tolerate or do not respond to traditional urate-lowering therapies (ULTs) \[[@CR9]\], while others are non-compliant with their ULT medication \[[@CR10]\]. In these patients, sUA levels remain over 6 mg/dl and urate deposition continues, resulting in continued flares, enlarging/persistent tophi, and ongoing erosive damage. Reducing sUA to within treatment target is of extreme importance to improve patient health and improve quality of life. Tophi and frequent gout flares have both been associated with decreased quality of life and disability in patients with controlled \[[@CR11]\] and refractory \[[@CR12]\] gout.

Pegloticase (pegylated recombinant uricase enzyme), a medication approved by the United States Food and Drug Administration (FDA) for uncontrolled gout, converts uric acid to readily excretable allantoin and is highly effective in lowering sUA \[[@CR13]\]. In fact, pegloticase has been shown to rapidly resolve tophi in patients who respond to therapy (i.e., maintain sUA below 6 mg/dl) \[[@CR14]\]. However, the proportion of patients who maintained a therapeutic response (sUA \< 6 mg/dl) during treatment months 3 and 6 was only 42% \[[@CR13]\]. Additionally, approximately one-quarter of patients experience an infusion reaction in the absence of pre-infusion uric acid monitoring \[[@CR13]\]. Studies have associated the development of anti-drug antibodies with both loss of efficacy (accelerated drug clearance) and infusion reactions \[[@CR15]--[@CR17]\]. Because pegloticase is both highly efficacious in therapy responders and there are very limited treatment options for gout that is refractory to standard ULTs, efforts have been made to attenuate anti-pegloticase antibody formation. A limited number of case reports in the literature suggest that pegloticase/immunomodulation co-therapy may minimize or prevent anti-drug antibody formation and allow more patients to complete a full course of therapy \[[@CR17]--[@CR25]\]. However, published reports have only included a limited number of patients and varied in immunomodulatory agent and dosing parameters. The current case series retrospectively investigated the role of methotrexate co-treatment on pegloticase responder rates. Treatment parameters (e.g., number of infusions, treatment duration), number of gout flares, and therapy safety were also examined.

Methods {#Sec2}
=======

This retrospective, chart review study was reviewed and approved by the Western Institutional Review Board (IRB; Puyallup, WA; registration number: IRB00000533). The IRB assigned the study exempt status, waiving the requirement of informed consent. All patients with uncontrolled gout who began pegloticase therapy (8 mg every 2 weeks) between January 2017 and September 2019 and were co-treated with methotrexate were included. All patients were cared for by a single physician (JAA) at a community medical practice.

All data were retrospectively collected from the medical records and were recorded in a de-identified manner. Data were collected using a standardized form and included subject demographics, disease characteristics, comorbidities, serial sUA levels, methotrexate treatment details, and specific safety information (e.g., gout flare, infusion reaction, laboratory values). The main outcome measure was the proportion of therapeutic responders, defined as those patients fulfilling the following conditions: (1) had a pegloticase therapy course of at least 12 biweekly infusions and (2) had an sUA \< 6 mg/dl immediately prior to infusion 12. Though not always considered a full course of therapy, 12 infusions was chosen for comparison to the length of treatment in the randomized clinical trials of pegloticase. The total number of pegloticase infusions administered, therapy duration, and the safety of using these medications in combination were also examined. Patients who discontinued methotrexate for any reason were still included and considered a responder if they met the outcome criteria.

Results {#Sec3}
=======

A total of ten patients with uncontrolled gout were included (Table [1](#Tab1){ref-type="table"}). Average subject age was 52.3 ± 13.5 years and nine patients (90%) were male. All patients had subcutaneous tophi as well as severe manifestations of gout, including numerous ulcerated tophi, recurrent gout flares, chronic pain, erosive damage on X-ray, or recurrent hospitalizations. These led to a markedly decreased quality of life in all patients and an inability to work in the majority of patients. Oral ULT use prior to pegloticase had included allopurinol (seven patients, 300 mg/day; two patients, 100 mg/day) and febuxostat (one patient, 40 mg/day). Allopurinol/febuxostat doses were not increased to maximum doses because of drug intolerance, kidney concerns, patient noncompliance, and/or the need for rapid tophi resolution.

At the time of pegloticase therapy initiation, average sUA was 9.42 ± 2.05 mg/dl, with all patients having an sUA above target (range, 5.7--13.1 mg/dl). Individual patient comorbidities are listed in Table [1](#Tab1){ref-type="table"} and included hypertension, coronary artery disease, diabetes, diabetic neuropathy, dyslipidemia, osteoarthritis, chronic kidney disease (CKD), kidney stones, and chondrocalcinosis of the wrist. All patients had at least one comorbidity, 80% had at least two comorbidities, and 60% had three or more comorbidities. Mean eGFR (calculated from serum creatinine levels \[[@CR26]\]) was 78.4 ± 22.5 ml/min/1.73 m^2^. Per the practice's standard prophylactic infusion protocol, all patients were administered oral fexofenadine (60 mg) the night before each pegloticase infusion and intravenous solumedrol (125 mg) and oral fexofenadine (60 mg) immediately prior to each infusion.Table 1Subject demographic and clinical characteristicsPatientGenderAge (years)BMI (kg/m^2^)Pre-therapy sUA (mg/dl)SubQ tophieGFR^a^ (ml/min/1.73 m^2^)Comorbidities1Male7728.29.6Yes37HTN, CKD, CAD, DM, DL, lower lid mass2Male6127.99.0Yes91DM, DL, OA, bipolar disorder3Male4532.18.0Yes111HTN, anxiety4Male6426.95.7Yes59CKD5Male5725.28.1Yes60OA6Male5530.011.6Yes74HTN, CKD, DM, OA, DN, history of AKI7Male2922.99.5Yes106HTN, anxiety, polyarthralgia8Female4031.513.1Yes84HTN, rheumatoid arthritis9Male4930.210.6Yes76HTN, OA, kidney stone10Male4629.09.0Yes86HTN, OA, chondrocalcinosis (wrist)Mean ± SD52.3 ± 13.528.4 ± 2.89.42 ± 2.0510 (100%)78.4 ± 22.5*sUA* serum uric acid levels; *SubQ* subcutaneous; *eGFR* estimated glomerular filtration rate; *SD* standard deviation; *HTN* hypertension; *CAD* coronary artery disease; *DM* diabetes mellitus; *DL* dyslipidemia; *OA* osteoarthritis; *CKD* chronic kidney disease; *DN* diabetic neuropathy; *AKI* acute kidney injury^a^Calculated using serum creatinine levels using the abbreviated MDRD equation \[[@CR23]\]

All patients were co-treated with pegloticase and methotrexate, as detailed in Table [2](#Tab2){ref-type="table"}. Nine (90%) patients began subcutaneous methotrexate (25 mg/week) an average of 19.9 ± 7.0 days prior to the first pegloticase infusion (range, 14--35 days before pegloticase). The remaining patient began oral methotrexate (12.5 mg/week) 14 days after beginning pegloticase therapy, just prior to the third pegloticase infusion. Once initiated, all patients were administered methotrexate on a weekly basis and daily oral folic acid (1 mg/day) for the duration of pegloticase therapy. Eight of ten patients (80%) were pegloticase responders, receiving at least 12 biweekly pegloticase infusions with an sUA below 6.0 mg/dl just prior to infusion 12. All ten included patients had an initial, rapid decrease in sUA after initiating pegloticase therapy (Fig. [1](#Fig1){ref-type="fig"}). However, two patients stopped pegloticase therapy before receiving 12 infusions and were not considered responders. Patient 5 had a loss of response (pre-infusion sUA increased to 6.6 mg/dl) in conjunction with a mild infusion reaction (skin rash, itching) during infusion 4. The patient was successfully treated with intravenous push anti-histamines (25 mg diphenhydramine HCl) and oral glucocorticoids (10 mg prednisone at time of infusion reaction followed by 20 mg/day for 5 days). Patient 6, who was responding to therapy, experienced a gout flare on the day of infusion 5. One week after infusion 5, this patient had a non-medical methotrexate injection issue and was lost to follow-up. The patient did not return for subsequent clinical follow-up or further pegloticase infusion.Table 2Methotrexate treatment and pegloticase response parametersPatientMethotrexatePegloticaseCo-therapy initiation (days)RouteDose (mg/week)Number of infusions^a^Therapy duration^b^ (weeks)sUA at final infusion (mg/dl)RespondereGFR at final infusion^c^ (ml/min/1.73 m^2^)Adverse events1 + 14oral12.52148.30.1Yes39--2− 35subQ251225.00.2Yes104--3− 21subQ252039.10.2Yes111Mild, transient ↑LFT4− 21subQ251324.00.2Yes65--5− 14subQ2546.06.6No--IR, dizziness6^d^− 14subQ2558.10.2No--Acute gout flare7− 25subQ251940.30.1Yes121--8− 21subQ251327.00.2Yes74Mild ↑LFT, pancytopenia9^e^− 14subQ251222.10.2Yes68--10^e^− 14subQ251428.30.2Yes97--All patients− 16.5 ± 12.613.3 ± 5.726.8 ± 13.40.8 ± 2.08 (80%)--Responders− 17.1 ± 14.215.5 ± 3.831.8 ± 9.50.2 ± 0.084.9 ± 27.9Day 0 defined as the date of the first pegloticase infusion. Baseline eGFR was 86.2 ± 25.5 ml/min/1.73 m^2^ in patients with a final infusion eGFR*subQ* subcutaneous; *IR* infusion reaction; *LFT* liver function test^a^Eight mg infusions administered biweekly^b^Therapy duration calculated as time between first and last recorded pegloticase dose^c^eGFR calculated from serum creatinine using the abbreviated MDRD equation \[[@CR23]\]^d^Indicates lost to follow-up^e^Indicates on-going pegloticase treatmentFig. 1Serial pre-infusion serum uric acid levels (sUA) in patients with uncontrolled gout who were co-treated with pegloticase and methotrexate. Day 0 was defined as the date of the first pegloticase infusion. Patients 5 and 6 were considered non-responders because of therapy discontinuation after infusion 4 (infusion reaction with sUA of 6.6 mg/dl) and loss of follow-up after infusion 5, respectively

No new safety concerns were identified. As stated above, one patient (Patient 6) reported a gout flare. One patient (Patient 5) had a loss of response (increased sUA levels) in conjunction with a mild infusion reaction (3--4 h duration; urticaria and erythema on face, neck, arms and trunk; dizziness). The infusion was stopped and the patient was administered 25 mg intravenous diphenhydramine. All symptoms quickly resolved, with the exception of minor dizziness. Pegloticase therapy was discontinued in this patient.

All liver function tests (LFTs), blood counts, and laboratory values remained stable during therapy in all but two patients (Table [2](#Tab2){ref-type="table"}). Patient 3 had a mild, transient increase in LFTs (ALT = 68 U/L) prior to infusion 13 (coincident with alcohol consumption). The patient was advised to minimize alcohol use and the event resolved without intervention. The patient continued both methotrexate and pegloticase therapy, receiving an additional seven infusions without further issue and remained a treatment responder. Patient 8 did not disclose her alcohol use prior to therapy and had a mild, transient increase in LFTs (value not available; outside system) with concurrent pancytopenia. LFTs values returned to normal following methotrexate discontinuation and decreased alcohol consumption. Pancytopenia improved with brief hospitalization, red blood cell transfusion and methotrexate discontinuation. The patient received an additional four infusions of pegloticase (without methotrexate) without further adverse event and remained a responder throughout the treatment period. Kidney function remained stable (eGFR), with no patients developing new CKD or experiencing a worsening of existing CKD.

Discussion {#Sec4}
==========

The current case series strongly suggests that immunomodulation therapy with methotrexate is effective in suppressing anti-drug antibody development in uncontrolled gout patients undergoing pegloticase therapy. In the current study, most patients began immunomodulation with subcutaneous methotrexate (25 mg/week) prior to the first pegloticase infusion, but one patient, who was a responder, began oral methotrexate (12.5 mg/week) 14 days after the first pegloticase infusion. Eight of ten patients (80%) tolerated at least 12 biweekly pegloticase infusions and remained responders during their course of treatment (duration of 31.8 ± 9.5 weeks, *n* = 8 responders). In contrast, only 42% of patients in the pegloticase clinical trials were treatment responders, with non-responders at a higher risk for ADA-induced infusion reactions \[[@CR13]\]. These findings are of particular importance because pegloticase is the only FDA-approved therapy for uncontrolled gout.

Methotrexate and azathioprine have been shown to attenuate biologic anti-drug antibody formation in patients being treated for autoimmune diseases such as rheumatoid arthritis \[[@CR27]\], spondyloarthropathies \[[@CR28]\], and inflammatory bowel disease \[[@CR29]--[@CR31]\]. Oral methotrexate use with pegloticase has been previously reported in a limited number of cases \[[@CR18], [@CR21], [@CR22], [@CR24]\]. Bessen et al. \[[@CR18], [@CR22]\] reported a responder rate of 100% in six patients using methotrexate as the only immunomodulator. An additional responder was also reported in a patient who was initially administered methotrexate, but was switched to azathioprine because of ongoing fatigue \[[@CR22]\]. In a series of ten cases \[[@CR21]\] and an open-label clinical trial of 14 patients \[[@CR24]\], response rates of 100% \[[@CR21]\], and 79% \[[@CR24]\], respectively, were observed with oral methotrexate/pegloticase co-therapy (methotrexate initiated approximately 1 month prior to pegloticase in both studies). Some success has also been observed with other immunomodulators, including azathioprine \[[@CR20], [@CR25]\], leflunomide \[[@CR23]\], mycophenolate mofetil \[[@CR17], [@CR19]\], and cyclosporine \[[@CR17], [@CR19], [@CR22]\].

Our findings with oral and subcutaneous methotrexate immunomodulation are in agreement with studies and case reports in the literature. Adverse events reported included a gout flare in one patient and a mild infusion reaction associated with a loss of sUA response in another patient, both known effects of pegloticase. One patient experienced a mild, transient LFT elevation and pancytopenia, both known methotrexate side effects, and one patient experienced a mild, transient LFT elevation, which was deemed alcohol related.

This study had several limitations. First, the retrospective design may have introduced errors from a selection bias. Second, our conclusions are based on a limited number of patients and there was no direct comparison cohort. Therefore, further prospective, controlled trials in a larger group of patients are needed to confirm the overall pegloticase responder rate when patients are co-treated with methotrexate and to determine the optimal immunomodulatory regimen. Such a trial to examine the efficacy and safety of oral methotrexate with pegloticase co-therapy is currently underway (MIRROR RCT, NCT03994731).

Conclusions {#Sec5}
===========

This case series demonstrated an 80% pegloticase response rate in patients with uncontrolled gout co-treated with methotrexate. Results presented here and in the literature suggest that immunomodulation co-therapy with methotrexate may allow more patients to be pegloticase responders with a favorable risk/benefit ratio.
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